# PF4

## Overview
Platelet factor 4 (PF4) is a gene that encodes a small cytokine belonging to the CXC chemokine family, specifically known as CXCL4. The protein product, platelet factor 4, is primarily synthesized by megakaryocytes and stored in the alpha-granules of platelets. Upon platelet activation, PF4 is released into the bloodstream, where it plays a crucial role in modulating coagulation and immune responses. As a chemokine, PF4 is involved in various physiological processes, including hematopoiesis, angiogenesis, and inflammation. It acts as a negative regulator of megakaryocytopoiesis and angiogenesis, inhibiting the proliferation of megakaryocyte progenitor cells and endothelial cells, respectively (Maurer2006Roles). PF4's interactions with glycosaminoglycans, such as heparin, are significant in clinical contexts, particularly in conditions like heparin-induced thrombocytopenia (HIT), where it forms complexes that can trigger immune responses (Niu2020Platelet; Kreimann2014Binding). The structural and functional characteristics of PF4 underscore its importance in maintaining vascular homeostasis and its potential therapeutic applications in angiogenesis-related diseases.

## Structure
The molecular structure of human platelet factor 4 (PF4) is characterized by a tetrameric assembly composed of four identical subunits, each containing residues 7-70, 107-170, 207-270, and 307-370 (Zhang1994Crystal). The primary structure of PF4 consists of 70 amino acids, forming a polypeptide chain (Zhang1994Crystal). The secondary structure includes a random coil or extended loop region, a three-strand antiparallel beta-sheet, and an alpha-helical region. The random coil region is stabilized by disulfide bonds, while the beta-sheet regions are involved in hydrogen bonding that maintains dimer formation (Zhang1994Crystal).

The tertiary structure of PF4 is compact and globular, stabilized by disulfide bonds and other noncovalent interactions, including electrostatic interactions and hydrogen bonding (Zhang1994Crystal). The quaternary structure is a tetramer, stabilized by interactions between beta-sheets and alpha-helices, as well as salt bridges and beta-sheet-like structures in the N-termini of dimers (Zhang1994Crystal). The tetrameric structure is further supported by a positively charged ring of lysine and arginine side chains, which provides potential sites for heparin binding (Zhang1994Crystal). The structure of human PF4 is similar to that of bovine PF4, with a root mean square deviation of 0.879 Å for 248 C-alpha atoms (Zhang1994Crystal).

## Function
Platelet factor 4 (PF4), also known as CXCL4, is a chemokine involved in several critical physiological processes in healthy human cells. It is primarily synthesized by megakaryocytes and stored in the alpha-granules of platelets. Upon platelet activation, PF4 is released into circulation, where it can bind to glycosaminoglycans (GAGs) such as heparin, heparan sulfate, and dermatan sulfate, with heparin having the highest affinity (Maurer2006Roles).

PF4 plays a significant role in hematopoiesis by acting as a negative regulator of megakaryocytopoiesis, inhibiting the proliferation and maturation of megakaryocyte progenitor cells. This inhibitory effect is dose-dependent and has been observed in various progenitor cell types, including human bone marrow MK progenitor cells (Maurer2006Roles). PF4 also supports the survival of hematopoietic cells by reducing their chemosensitivity to cytotoxic agents, enhancing their recovery post-treatment (Han1997Platelet).

In angiogenesis, PF4 acts as a negative regulator by inhibiting endothelial cell proliferation and migration, crucial for new blood vessel formation. It binds to and inhibits the growth of endothelial cells and interacts with angiogenesis growth factors like fibroblast growth factors (FGF) and vascular endothelial growth factors (VEGF), inhibiting their interaction with cell surface receptors (Maurer2006Roles). These functions highlight PF4's role in regulating blood cell formation and maintaining vascular homeostasis.

## Clinical Significance
Platelet factor 4 (PF4) is implicated in several clinical conditions, particularly heparin-induced thrombocytopenia (HIT). HIT is a severe immune-mediated adverse reaction to heparin, where antibodies form against complexes of PF4 and heparin, leading to platelet activation and thrombocytopenia. Specific amino acids in PF4 are crucial for binding pathogenic antibodies in HIT, and mutations in these amino acids can alter antibody interactions. For instance, mutations such as C10A, C12A, C36A, and C52A significantly reduce binding to pathogenic HIT antibodies, which may help distinguish between pathogenic and non-pathogenic antibodies in diagnostic settings (Huynh2019Characterization).

PF4 also plays a role in angiogenesis and tumor growth. It inhibits blood vessel proliferation and endothelial cell migration by blocking fibroblast growth factor 2 (FGF-2) binding to its receptor. PF4's anti-angiogenic properties have been explored for therapeutic applications, such as inhibiting tumor growth and neovascularization in mouse models (Maurer2006Roles). Alterations in PF4 expression or function, such as those induced by mutations or interactions with heparin, can lead to significant clinical outcomes, highlighting its importance in both coagulation and immune responses (Kreimann2014Binding).

## Interactions
Platelet Factor 4 (PF4) is known for its interactions with several proteins involved in coagulation. PF4 binds with high affinity to heparin, a negatively charged glycosaminoglycan, forming complexes that can trigger immune responses, such as heparin-induced thrombocytopenia (HIT) (Niu2020Platelet; Kreimann2014Binding). PF4 also interacts with glycanated forms of thrombomodulin and protein C. It binds to the chondroitin sulfate glycosaminoglycan (GAG) domain of thrombomodulin and the γ-carboxyglutamic acid (Gla) domain of protein C, enhancing the conversion of protein C to activated protein C (APC) by the thrombin-thrombomodulin complex (Dudek1997Platelet). This interaction is calcium-independent and likely electrostatic, suggesting that PF4's cationic nature facilitates its binding to these anionic domains (Dudek1997Platelet).

PF4 also associates with the platelet cytoskeleton and is expressed on the platelet surface, with its surface expression being enhanced in thrombin-stimulated platelets (CAPITANIO1985Interaction). These interactions highlight PF4's role in modulating coagulation and its potential impact on immune responses.


## References


[1. (Niu2020Platelet) Chendi Niu, Yang Yang, Angela Huynh, Ishac Nazy, and Igor A. Kaltashov. Platelet factor 4 interactions with short heparin oligomers: implications for folding and assembly. Biophysical Journal, 119(7):1371–1379, October 2020. URL: http://dx.doi.org/10.1016/j.bpj.2020.04.012, doi:10.1016/j.bpj.2020.04.012. This article has 12 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.bpj.2020.04.012)

[2. (Huynh2019Characterization) Angela Huynh, Donald M. Arnold, John G. Kelton, James W. Smith, Peter Horsewood, Rumi Clare, Alba Guarné, and Ishac Nazy. Characterization of platelet factor 4 amino acids that bind pathogenic antibodies in heparin‐induced thrombocytopenia. Journal of Thrombosis and Haemostasis, 17(2):389–399, February 2019. URL: http://dx.doi.org/10.1111/jth.14369, doi:10.1111/jth.14369. This article has 35 citations and is from a peer-reviewed journal.](https://doi.org/10.1111/jth.14369)

[3. (Dudek1997Platelet) Arkadiusz Z. Dudek, Christopher A. Pennell, Troy D. Decker, Tish A. Young, Nigel S. Key, and Arne Slungaard. Platelet factor 4 binds to glycanated forms of thrombomodulin and to protein c. Journal of Biological Chemistry, 272(50):31785–31792, December 1997. URL: http://dx.doi.org/10.1074/jbc.272.50.31785, doi:10.1074/jbc.272.50.31785. This article has 42 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.272.50.31785)

[4. (Kreimann2014Binding) Martin Kreimann, Sven Brandt, Krystin Krauel, Stephan Block, Christiane A. Helm, Werner Weitschies, Andreas Greinacher, and Mihaela Delcea. Binding of anti–platelet factor 4/heparin antibodies depends on the thermodynamics of conformational changes in platelet factor 4. Blood, 124(15):2442–2449, October 2014. URL: http://dx.doi.org/10.1182/blood-2014-03-559518, doi:10.1182/blood-2014-03-559518. This article has 69 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1182/blood-2014-03-559518)

[5. (CAPITANIO1985Interaction) A CAPITANIO, S NIEWIAROWSKI, B RUCINSKI, G TUSZYNSKI, C CIERNIEWSKI, D HERSHOCK, and E KORNECKI. Interaction of platelet factor 4 with human platelets. Biochimica et Biophysica Acta (BBA) - General Subjects, 839(2):161–173, April 1985. URL: http://dx.doi.org/10.1016/0304-4165(85)90033-9, doi:10.1016/0304-4165(85)90033-9. This article has 61 citations.](https://doi.org/10.1016/0304-4165(85)90033-9)

[6. (Maurer2006Roles) Anne-Marie Maurer, Bin Zhou, and Zhong Chao Han. Roles of platelet factor 4 in hematopoiesis and angiogenesis. Growth Factors, 24(4):242–252, January 2006. URL: http://dx.doi.org/10.1080/08977190600988225, doi:10.1080/08977190600988225. This article has 31 citations and is from a peer-reviewed journal.](https://doi.org/10.1080/08977190600988225)

[7. (Han1997Platelet) Zhong Chao Han, Min Lu, Junmin Li, Mai Defard, Bernadette Boval, Nicole Schlegel, and Jacques P. Caen. Platelet factor 4 and other cxc chemokines support the survival of normal hematopoietic cells and reduce the chemosensitivity of cells to cytotoxic agents. Blood, 89(7):2328–2335, April 1997. URL: http://dx.doi.org/10.1182/BLOOD.V89.7.2328, doi:10.1182/blood.v89.7.2328. This article has 125 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1182/BLOOD.V89.7.2328)

[8. (Zhang1994Crystal) Xiaohua Zhang, Liqing Chen, Daniel P. Bancroft, C. K. Lai, and Theodore E. Maione. Crystal structure of recombinant human platelet factor 4. Biochemistry, 33(27):8361–8366, July 1994. URL: http://dx.doi.org/10.1021/bi00193a025, doi:10.1021/bi00193a025. This article has 149 citations and is from a peer-reviewed journal.](https://doi.org/10.1021/bi00193a025)